LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » World News

Gilead to buy Kite for promising cancer therapies in $12 billion deal

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Updated: Mon, Aug 28, 2017
09:23 pm
Reuters
RELATED NEWS
Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi
RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged
Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details
Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities
#GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here #GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

Santa Monica, California-based Kite is developing chimeric antigen receptor T-cell therapy, known as a CAR T, which harnesses the body`s own immune cells to recognize and attack malignant cells.

Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over Kite`s Friday close.

Kite`s shares rose 28 percent to $178.65 in morning trading, while Gilead`s shares rose 2.8 percent to $75.86.

Recent breakthroughs convinced Gilead`s management that they needed to buy a company developing CAR T treatments.

"It really became clear that it was going to work and it was going to work in more than one kind of tumor... And then, importantly, that the manufacturing on an industrial scale could work," Gilead Chief Executive John Milligan told investors on a conference call. "Now is the right time to get involved in this kind of therapy."

Gilead`s growth has been fueled by its pricey but revolutionary hepatitis C drugs but with fewer eligible patients and rising competition, sales have begun to fall.

Second-quarter sales of its hepatitis C drugs - Sovaldi, Harvoni and Epclusa - totaled $2.9 billion, down from $4 billion a year earlier.

Kite is one of the leading players in the emerging field of CAR T, and is competing with rivals Novartis AG, Juno Therapeutics Inc and Bluebird Bio Inc in a race to get the first approved therapy.

Juno shares rose 15 percent and Bluebird shares rose 10 percent in morning trading on hopes that other deals in the sector will follow.

If approved, these drugs are expected to cost up to $500,000 and generate billions of dollars in sales. Success would also help advance a cancer-fighting technique that scientists have been trying to perfect for decades.

The U.S. Food and Drug Administration (FDA) is expected to decide by Nov. 29 whether to approve Kite`s CAR T, axi-cel, for treatment of adults with advanced lymphoma.

Wall Street and Gilead shareholders have long been expecting Gilead to use its cash pile for a big-ticket acquisition. Gilead is hoping the deal, expected to close in the fourth quarter, repeat the success of its 2011 purchase of Pharmasset.

That deal allowed Gilead, then the world`s largest maker of HIV drugs, to move into hepatitis C treatments. Last year, just under half of Gilead`s $30 billion in sales came from hepatitis C treatments.

The company faced strong criticism for the steep price tag on those treatments, and the cost of Kite`s CAR T offerings will likely generate backlash for the company as well.

"There will be headlines just because the price itself is so high," said Brad Loncar, CEO of Loncar Investments, which runs the Loncar Cancer Immunotherapy ETF. "But unlike hepatitis C, they are treating patients that only have weeks or months to live and providing durable remissions."

BofA Merrill Lynch and Lazard are Gilead`s financial advisers, while Centerview Partners is advising Kite.

Skadden is Gilead`s legal counsel and Sullivan & Cromwell and Cooley are working with Kite.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Economy
RELATED NEWS
Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi
RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged
Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details
Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities
#GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here #GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here

LATEST NEWS

Taarak Mehta Ka Ooltah Chashmah fee per episode: Dilip Joshi, Munmun Dutta, Shailesh Lodha, Mandar Chandwadkar, Amit Bhatt—how much they earn

Stocks in Focus on April 16: Wipro, Auto Stocks, NFL, Philip Carbon to Tata Power; here are the 5 Newsmakers of the Day

CBSE class 10 promotion criteria, class 12 board exam dates and will ICSE Class 10, 12 exams be postponed?—All you need to know

NEET PG 2021 exam: After CBSE, NEET aspirants want exam to be postponed; decision on ICSE Class 10, Class 12 exams likely soon

Board exam 2021 Class 10, 12 latest news: Check list of states that postponed, cancelled board exams; is yours here? CHECK

Gold Price today 15-04-2021: Expert says buy for a target of Rs 48600 - money making tip

SBI stock still under spotlight, expert says BUY with target price of Rs 368

Shubho noboborsho 2021: Send best pohela boishakh WhatsApp stickers, GIFs, messages, status and more

ICICI Bank, Axis Bank, and HDFC Bank: Technical details highlighted for readers

Infosys share price today: Expert says buy in Rs 1320-Rs 1340 range even as results below expectations

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved